Biocept (BIOC) Upgraded to “Hold” by Zacks Investment Research

Biocept (NASDAQ:BIOC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. “

Other equities analysts also recently issued research reports about the company. ValuEngine raised Biocept from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Westpark Capital downgraded Biocept from an “outperform” rating to a “hold” rating in a research report on Wednesday, May 23rd.

Shares of Biocept stock traded up $0.08 on Monday, hitting $3.29. The stock had a trading volume of 201,883 shares, compared to its average volume of 235,360. Biocept has a twelve month low of $2.86 and a twelve month high of $44.10. The company has a current ratio of 1.20, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $7.30 million, a price-to-earnings ratio of -0.14 and a beta of 1.75.

Biocept (NASDAQ:BIOC) last posted its earnings results on Tuesday, August 14th. The medical research company reported ($2.70) EPS for the quarter, beating the consensus estimate of ($3.30) by $0.60. Biocept had a negative return on equity of 587.80% and a negative net margin of 642.49%. The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $1.09 million. equities research analysts predict that Biocept will post -9.01 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Biocept stock. BlackRock Inc. grew its position in Biocept Inc (NASDAQ:BIOC) by 1.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 794,302 shares of the medical research company’s stock after purchasing an additional 14,403 shares during the quarter. BlackRock Inc. owned about 34.99% of Biocept worth $159,000 as of its most recent SEC filing.

About Biocept

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Read More: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on Biocept (BIOC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.

Leave a Reply